DocWire News Editors

DocwireNews

A study assessed how treatment regularity among patients receiving intravitreal aflibercept injections for neovascular age-related macular degeneration (AMD) impacts visual acuity outcomes.The study included patients enrolled in the PERSEUS trial who received at least seven injections during the first year (n=370). Patients were stratified into treatment-na&iuml;ve and previously treated subgroups and were further compared by whether they received regular (n=209) or irregular (n=161) treatment. Regular treatment was defined as three months of monthly intravitreal aflibercept injections followed by bimonthly injections until month 12. Irregular treatment was defined as anything other than regular treatment, assuming patients received at least seven injections. The main outcome was mean 12-month change in visual acuity; additional outcomes included visual acuity gain or loss, proportion of patients achieving reading vision, and percentage of patients with fluid.The mean (&plusmn; standard deviation [SD]) 12-month improvement in visual acuity was greater in the regular cohort (6.1&thinsp;&plusmn;&thinsp;15.6 Early Treatment Diabetic Retinopathy Study letters) compared with the irregular cohort (2.5&thinsp;&plusmn;&thinsp;16.7 letters) (P=0.0514). The treatment-na&iuml;ve regular subgroup had the best outcomes, with a mean (&plusmn; SD) visual acuity improvement of 8.0 &plusmn; 17.7 letters&mdash;significantly greater compared with the treatment-na&iuml;ve irregular treatment subgroup (2.8 &plusmn; 20.0 letters). Among treatment-na&iuml;ve patients, irregular treatment was consistently predictive of inferior outcomes. A greater proportion of treatment-na&iuml;ve patients had a worsening of at least five letters in the irregular treatment group compared with the regular treatment group (29.6% vs. 13.6%; P=0.0049), but treatment-na&iuml;ve irregular patients had a significantly higher mean (&plusmn; SD) number of injections than the regular patients (8.0 &plusmn; 1.2 vs. 7.4 &plusmn; 0.6; P=0.0001). Treatment-na&iuml;ve irregular patients, compared with regular patients, had more visits (19.1 &plusmn; 8.6 vs. 16.1 &plusmn; 5.7), visual acuity tests (14.2&thinsp;&plusmn;&thinsp;6.9 vs. 12.0&thinsp;&plusmn;&thinsp;4.6), and optical coherence tomography examinations (5.1&thinsp;&plusmn;&thinsp;3.7 vs. 3.4.0&thinsp;&plusmn;&thinsp;3.0).The researchers concluded that despite having more visits and injections than regularly treated patients with neovascular AMD, patients who receive irregular intravitreal aflibercept injections for their disease had poorer visual acuity outcomes.

MarkAlain Déry, DO

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Regularity of Aflibercept Treatment Affects AMD Outcomes

Ophthalmology

A study assessed how treatment regularity among patients receiving intravitreal aflibercept injections for neovascular age-related macular degeneration (AMD) impacts visual ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe